hyperproduction of the chromosomal enzymes, as well as resistant strains without synergy, were disregarded. During the first period, 15 (2.1%) of 707 outpatients were carriers of *Escherichia coli* (14 patients) or *Proteus mirabilis* (1 patient) with ESBL. This percentage increased during the second period, when 17 (3.8%) of 454 outpatients were carriers of *E. coli* with ESBL, and again in the third period, when 12 (7.5%) of 160 were carriers of *E. coli* (11 patients) or *Enterobacter cloacae* (1 patient) with ESBL. Characterization of the different ESBL isolated during the three study periods is in process. Although *Klebsiella pneumoniae* carrying ESBL has been detected in our hospital (7), as well as in other hospitals in Barcelona (8), no ESBL-producing *K. pneumoniae* strains were identified in this survey.

Although we did not disregard either the patients’ previous treatment with antibiotics or previous hospitalization, these patients came to the hospital from the community carrying strains that express ESBL. Moreover, during these three periods we observed a significant increase in the frequency of ESBL carriers (from 2.1% to 7.5%; p<0.005). These data suggest that the community could be a reservoir for these enzymes, as occurs with other microorganisms (9–11).

Many questions remain unanswered regarding the diffusion mechanisms of this resistance in the community. Confirmation of community-based transmission of ESBL would indicate a need for heightened vigilance and further studies to determine the reservoirs and vehicles for dissemination of ESBL within the community.

**Beatriz Mirelis,* † Ferran Navarro, † Elisenda Miró, † Raul Jesús Mesa,* Pere Coll,* † and Guillem Prats †**

*Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; and †Universitat Autònoma de Barcelona, Barcelona, Spain*

**References**

1. Britàs L, Zarazaga M, Saenz Y, Ruiz-Larrea F, Torres C. β-Lactamases in ampicillin-resistant *Escherichia coli* isolates from foods, humans, and healthy animals. Antimicrob Agents Chemother 2002;46:3156–63.

2. Österblad M, Hakonen A, Manninen R, Leistevuo T, Peltonen R, Meurman O, et al. A between-species comparison of antimicrobial resistance in enterobacteria in fecal flora. Antimicrob Agents Chemother 2000;44:1479–84.

3. Murray P, Baron E, Pfaffer M, Tenover F, Yolken R. Manual of clinical microbiology. 7th ed. Washington: American Society for Microbiology; 1999.

4. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial disk susceptibility test. Document M2-A7. 7th ed. Wayne (PA): The Committee; 2000.

5. National Committee for Clinical Laboratory Standards. Supplemental tables: disk diffusion. Document M100-S10. Wayne (PA): The Committee; 2000.

6. Livermore DM. β-Lactamases in laboratory and clinical resistance. Clin Microbiol Rev 1995;8:557–84.

7. Sabaté M, Miró E, Navarro F, Vergés C, Aliaga R, Mirelis B, et al. Beta-lactamases involved in resistance to broad-spectrum cephalosporins in *Escherichia coli* and *Klebsiella* spp. clinical isolates collected between 1994 and 1996, in Barcelona (Spain). J Antimicrob Chemother 2002;49:989–97.

8. Hernández JR, Pascual A, Cantón R, Martínez-Martínez L, Grupo de Estudio de Infección Hospitalaria (GEIH). *Escherichia coli* y *Klebsiella pneumoniae* productores de beta-lactamasas de espectro extendido en hospitales españoles (Proyecto GEIH-BLEE 2000). Enferm Infec Microb Clin 2003;21:77–82.

9. Chambers HF. The changing epidemiology of *Staphylococcus aureus*. Emerg Infect Dis 2001;8:178–82.

10. Garau J, Xercavins M, Rodriguez-Carballeira M, Gómez-Vera JR, Coll I, Vidal D, et al. Emergence and dissemination of quinolone-resistant *Escherichia coli* in the community. Antimicrob Agents Chemother 1999;43:2736–41.

11. Tomasz A. New faces of an old pathogen: emergence and spread of multidrug-resistant *Streptococcus pneumoniae*. Am J Med 1999;107:55S–62S.

**Polymyxin-Resistant Acinetobacter spp. Isolates: What Is Next?**

To the Editor: In Brazilian hospitals, *Acinetobacter* spp. has been an important etiologic agent of nosocomial infections, mainly pneumonia (1–3). In general, ampicillin/subbac-tam and carbapenems remain the last therapeutic options for treatment of such infections (3,4). However, resistance rates to carbapenems have increased, reaching rates approximately 12% or higher in some Brazilian hospitals (1,3,4). Thus, more toxic agents such as polymyxins have been used as alternative therapeu-tic drugs against multidrug-resistant *Acinetobacter* infections (5,6). The clinical use of polymyxins has been based on antimicrobial susceptibility results and previous clinical experience. However, the National Committee for Clinical Laboratory Standards (NCCLS) documents do not currently provide interpretative criteria for the testing of polymyxins (7). In addition, the disk diffusion technique was reported to be an unreliable method for evaluating the susceptibility to polymyxins (8). Since *Acinetobacter* clinical specimens exhibiting high MICs for polymyxins (MIC, 8–32 µg/mL) were recently detected, we searched for the frequency of occurrence of *Acinetobacter* spp. strains exhibiting reduced susceptibility to polymyxin B among 100 bloodstream isolates of *Acinetobacter* spp. (8). The bacterial isolates were consecutively collected between September 1999 and December 2000 from a tertiary Brazilian hospital,
where *Acinetobacter* spp. infections have reached endemic levels and polymyxins have been frequently used. Only one isolate per patient was included in the study.

The isolates were identified to the species level using the BBL Crystal System (Becton Dickinson, Sparks, MD). The susceptibility to polymyxin B and meropenem were tested by disk diffusion and agar dilution techniques according to NCCLS recommendations (9,10). The susceptibility interpretative criteria for meropenem and polymyxin B were based on the current and former NCCLS documents, respectively (7,11). The MIC was defined as the lowest antimicrobial concentration that inhibited bacterial growth. *Pseudomonas aeruginosa* ATCC 27853, *Staphylococcus aureus* ATCC 25923, and *Escherichia coli* ATCC 25922 were used as quality control strains. Testing errors and agreements were determined by comparing the results of the disk diffusion with the standard criterion agar dilution method. Categorical agreement was obtained when the isolates were classified within the same susceptibility category. The very major and former NCCLS documents, respectively (7,11).

Meropenem (MIC50, 1 µg/mL) and polymyxin B (MIC50, 1 µg/mL) showed similar in vitro potency. However, meropenem exhibited the highest susceptibility rate (99.0% susceptible). In contrast to previous studies, only one strain was resistant to meropenem (1,2,3,8), which indicates that the carbapenem-susceptibility rates among *Acinetobacter* spp. isolates may vary according to the period evaluated even in the same institution. By using the polymyxin B resistance breakpoint (MIC ≥4 µg/mL) presented by the former NCCLS document, which was recently validated, we found that five *Acinetobacter* spp. isolates were considered resistant to polymyxin B (MICs, 8–32 µg/mL) (8,11). All isolates were susceptible to meropenem and belonged to *A. baumannii* (4) and *A. lwoffi* (1) species. The polymyxin B–resistant isolates showed similar in vitro potency. The polymyxin B resistance may leave no alternative therapy. Since the emergence of polymyxin-resistant *Acinetobacter* spp. isolates, strict infection control measures must be adopted to avoid the emergence and spread of such isolates. The low accuracy of routine susceptibility tests, especially disk diffusion, may jeopardize rapid implementation of such measures.

Adriana O. Reis,* Deise A.M. Luz,* Maria C.B. Tognim,* Hélio S. Sader,* and Ana C. Gales*

*Universidade Federal de São Paulo, São Paulo, Brazil

References

1. Sader HS, Gales AC, Pfaller MA, Mendes RE, Zoccoli C, Barth A, et al. Pathogen frequency and resistance patterns in Brazilian hospitals: summary of results from three years of the SENTRY Antimicrobial Surveillance Program. Braz J Infect Dis 2001;5:200–14.
2. Gales AC, Jones RN, Forward KR, Linares J, Sader HS, Verhoef J. Emerging importance of multidrug-resistant *Acinetobacter* species and *Stenotrophomonas maltophilia* as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY Antimicrobial Surveillance Program (1997–1999). Clin Infect Dis 2001;32(Suppl 2):S104–13.
3. Levin AS, Mendes CM, Sinto SI, Sader HS, Scarpitta CR, Rodrigues E, et al. An outbreak of multiresistant *Acinetobacter baumanii* in a university hospital in São Paulo, Brazil. Infect Control Hosp Epidemiol 1996;17:366–8.
4. Gales AC, Sader HS, Siento S, Santos OP, Mendes CMF. In vitro activity of ampicillin-sulbactam against clinical multidrug-resistant *Acinetobacter baumannii* isolates. J Chemother 1996;8:416–9.
5. Go ES, Urban C, Burns J, Kreiswirth B, Eisner W, Mariano N, et al. Clinical and molecular epidemiology of *Acinetobacter*
Infections sensitive only to polymyxin B and sulbactam. Lancet 1994;344:1329–32.
6. Levin AS, Barone AA, Penco J, Santos MV, Marinho IS, Arruda EA, et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant *Pseudomonas aeruginosa* and *Acinetobacter baumannii*. Clin Infect Dis 1999;28:1008–11.
7. National Committee for Clinical Laboratory Standards (NCCLS). Performance standards for antimicrobial disk susceptibility testing. Document M100-S11. Wayne (PA): The Committee; 2002.
8. Gales AC, Reis AO, Jones RN. Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines. J Clin Microbiol 2001;39:183–90.
9. National Committee for Clinical Laboratory Standards (NCCLS). Methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically. 5th ed. Approved standard M7-A5. Wayne (PA): The Committee; 2000.
10. National Committee for Clinical Laboratory Standards (NCCLS). Performance standards for antimicrobial disk susceptibility tests. Approved standard M2-A7. Wayne (PA): The Committee; 2000.
11. National Committee for Clinical Laboratory Standards (NCCLS). Performance standards for antimicrobial disk susceptibility tests. Approved standard M2-A2 S2. Wayne (PA): The Committee; 1981.
12. Pfaffer MA, Sader HS, Hollis RJ. Chromosomal restriction fragment analysis by pulsed-field gel electrophoresis. Isenberg HD, editor. Vol. 1. Clinical microbiology procedures handbook. Washington: ASM Press; 1992. p. 1–12.
13. Sader HS, Mendes CF, Pignatari AC, Pfaffer MA. Use of macrorestriction analysis to demonstrate interhospital spread of multiresistant *Acinetobacter baumannii* in São Paulo, Brazil. Clin Infect Dis 1996;23:631–4.

Address for correspondence: Ana Cristina Gales, Laboratório Especial de Microbiologia Clínica, Division of Infectious Diseases, Universidade Federal de São Paulo, Rua Leandro Dupret, 188 São Paulo, SP, Brazil, CEP 04025-010; fax: (55-11) 5081-2819/5571-5180/5081-2965; email: galesac@aol.com

---

**Multidrug-Resistant Shiga Toxin-Producing *Escherichia coli* O118:H16 in Latin America**

To the Editor: We report the first isolation of a multiple antimicrobial drug–resistant strain of Shiga toxin–producing *Escherichia coli* (STEC) O118:H16 from cattle in Latin America. The strain was isolated during a study of fecal STEC in 205 healthy and 139 diarrheic cattle on 12 beef farms in the state of São Paulo, Brazil, in February 2000; one case of STEC was found in a 1-month-old calf with diarrhea. This bovine STEC O118:H16 strain showed resistance to eight antimicrobial substances; the following resistance (R)-genes were detected: ampicillin (*bla*TEM,like), kanamycin and neomycin (*aphA1*), streptomycin (*strA/B*), sulphamethoxazole (*sul2*), tetracyclin (*tetA*), trimethoprim (no *dfrA1, A5, A7, A12, A14, or A17*), and trimethoprim/sulphamethoxazol. The STEC O118: H16 strain from Brazil was found to be similar for virulence genes (Shiga toxin 1 [stx1], intimin beta 1 [eae B1], and EHEC-hemolysin [E-hlyA]) and for antimicrobial drug resistance to STEC O118:H16 strains, which were isolated in different countries of Europe (1). Beginning in 1986, STEC O118:H16 was identified as an emerging pathogen for calves and humans in Belgium and Germany (2–4). Cattle and human STEC O118:H16 isolates were similar in virulence attributes and antimicrobial drug resistance and belonged to a distinct genetic clone (1). Transmission of these pathogens from cattle to humans on farms was observed (5).

Beginning in 1996, STEC O118:H16 has become important as an emerging pathogen in humans and has been associated with bloody diarrhea and hemolytic uremic syndrome (2). Analysis of the antimicrobial resistance profiles showed that >96% of the European STEC O118:H16 strains showed resistance to one or more antimicrobial drugs in contrast to the 10% to 15% drug-resistant strains that were detected among STEC belonging to other serotypes (1,6,7). STEC O118:H16 showing multidrug-resistance in up to eight different antimicrobial drugs predominated among younger isolates, indicating that drug resistance genes have accumulated over time in STEC O118:H16 strains. The frequency of antimicrobial drug resistance in STEC and Stx-negative *E. coli* in humans and animals was compared in a study by Schroeder et al. (8). Among human clinical *E. coli* isolates, antimicrobial resistance was less frequently observed in STEC than in Stx-negative strains, whereas in cattle, antibiotic-resistant strains were found at similar frequencies in both groups of *E. coli*. The relatively higher frequency of antimicrobial-resistant STEC in cattle was explained by the use of antimicrobial drugs in cattle production, whereas human infections with STEC are generally not treated with antibiotics (8). Cattle could thus be an important source of new emerging antibiotic-resistant STEC strains such as O118:H16.

The genetic basis of antimicrobial resistance in STEC O118:H16 is broad, including R-plasmids, integrons, transposons, and chromosomally inherited drug-resistance genes. Fluoroquinolone resistance has also been acquired by some STEC O118:H16 strains (1). The heterogeneity of antimicrobial drug–resistance patterns, the increase of multidrug-resistant strains over time